A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-BASIS)

I4V-MC-JAHV -

The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.

Trial Summary

Age Range
2 - 17 years
Conditions the trial is for
Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib
Could I receive a Placebo?
Yes
Enrollment Goal
220
Trial Dates
Dec 17, 2018 - Jan 26, 2022
How long will I be in the trial?
The study will last about 44 weeks and may include up to 17 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active

  • Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)

Participants Must Not:

  • Participants must not have systemic JIA, with or without active systemic features

  • Participants must not have persistent oligoarticular arthritist

  • Participants must not have been previously treated with a Janus kinase (JAK) inhibitor

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.